ATE221663T1 - Prionbindende proteine und deren verwendungen - Google Patents

Prionbindende proteine und deren verwendungen

Info

Publication number
ATE221663T1
ATE221663T1 AT97927319T AT97927319T ATE221663T1 AT E221663 T1 ATE221663 T1 AT E221663T1 AT 97927319 T AT97927319 T AT 97927319T AT 97927319 T AT97927319 T AT 97927319T AT E221663 T1 ATE221663 T1 AT E221663T1
Authority
AT
Austria
Prior art keywords
binding proteins
prion
features
prpbps
prpbp
Prior art date
Application number
AT97927319T
Other languages
English (en)
Inventor
Neil R Cashman
Vincent Dodelet
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE221663T1 publication Critical patent/ATE221663T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97927319T 1996-05-29 1997-05-29 Prionbindende proteine und deren verwendungen ATE221663T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1838096P 1996-05-29 1996-05-29
PCT/IB1997/000827 WO1997045746A2 (en) 1996-05-29 1997-05-29 Prion protein binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
ATE221663T1 true ATE221663T1 (de) 2002-08-15

Family

ID=21787631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927319T ATE221663T1 (de) 1996-05-29 1997-05-29 Prionbindende proteine und deren verwendungen

Country Status (8)

Country Link
EP (1) EP0920630B1 (de)
JP (1) JP2000512131A (de)
AT (1) ATE221663T1 (de)
AU (1) AU3186397A (de)
BR (1) BR9709900A (de)
CA (1) CA2256312A1 (de)
DE (1) DE69714451T2 (de)
WO (1) WO1997045746A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197207B1 (en) * 1997-05-21 2001-03-06 Baxter International Inc. Method of reducing the possibility of transmission of spongiform encephalopathy diseases by blood products
WO1998053838A2 (en) * 1997-05-30 1998-12-03 Winnacker Ernst Ludwig A soluble laminin receptor precursor and methods to inhibit its interactions
DE19925073C2 (de) * 1999-06-01 2001-07-19 Stefan Weiss Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
US7569660B1 (en) 1999-06-09 2009-08-04 The University Of Chicago Recombinant prion-like proteins and materials comprising same
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
JP2003531356A (ja) * 1999-06-29 2003-10-21 マクギル ユニバーシティー プリオンタンパク質結合タンパク質及びそれらの使用
FR2801106B1 (fr) * 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
WO2002001224A1 (en) * 2000-06-27 2002-01-03 Chugai Seiyaku Kabushiki Kaisha Method of evaluating binding activity of ligand to ligand-binding protein
EP2301959A3 (de) 2002-04-09 2013-03-13 The Scripps Research Institute Mit motiven transplantierte hybrid-polypeptide und verwendungen davon
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
ES2531926T3 (es) * 2002-12-03 2015-03-20 North Carolina State University Ligandos de proteínas priones y procedimientos de uso
US20050054003A1 (en) * 2003-09-10 2005-03-10 Stenland Christopher J. Prion clearance using particulate metal oxides
DE102007016324A1 (de) * 2007-04-04 2008-10-09 Priontype Gmbh & Co.Kg Verfahren zum Nachweis von pathologisch verändertem Prion-Protein (PrPSc)
WO2014025785A2 (en) * 2012-08-06 2014-02-13 Trustees Of Boston University Prion protein ligands as therapeutic agents for neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246766B (it) * 1990-11-12 1994-11-26 Medea Res Srl N-((2-tenoilmercapto-3-metil)-butanoil)-omocisteina tiolattone, sua preparazione e suo uso come agente terapeutico
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes

Also Published As

Publication number Publication date
DE69714451T2 (de) 2003-01-30
CA2256312A1 (en) 1997-12-04
DE69714451D1 (de) 2002-09-05
AU3186397A (en) 1998-01-05
EP0920630B1 (de) 2002-07-31
BR9709900A (pt) 2000-01-25
JP2000512131A (ja) 2000-09-19
EP0920630A2 (de) 1999-06-09
WO1997045746A3 (en) 1998-04-09
WO1997045746A2 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
ITTO950367A0 (it) Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti.
ATE221663T1 (de) Prionbindende proteine und deren verwendungen
WO2000078344A8 (en) Prion protein peptides and uses thereof
DE69841175D1 (de) Interleukin-18 bindende proteine, deren herstellung und verwendung
EP2128260A3 (de) Modifizierte TGF-beta-Superfamilienproteine
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
WO2001004265A3 (en) C-terminal protein tagging
DE59806216D1 (de) Neue farbstoff-polysaccharid-konjugate und deren verwendung als diagnostikum
NO990328D0 (no) Fuserte polypeptider som omfatter et IGE-bindingsdomene og en HSA-komponent, og deres diagnostiske og terapeutiske bruk
FR2766193B1 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
ATE433992T1 (de) An menschlichen faktor-viii bindende moleküle und faktor-viii-ähnliche proteine
WO2001012806A3 (fr) 'odorant-binding' proteines humaines fixant des ligands hydrophobes: polypeptides et polynucleotides codant lesdits polypeptides et leurs applications
NZ500216A (en) Beta-amyloid peptide-binding proteins and pharmaceutical use
EP1018551A4 (de) Megsin-protein
EP1210110A4 (de) An prionprotein bindende proteine und deren verwendungen
EP1038958A4 (de) Menschliches nap1-protein
GB9811221D0 (en) Bacterial-pheromones and uses therefor
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
EP0885959A3 (de) Menschlisches Wnt-5b Protein
AU5137698A (en) Novel dna, novel protein, and novel antibody
EP1186662A3 (de) Prionbindendes Proteine und deren Verwendungen
AU3845395A (en) Antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
IT242042Y1 (it) Contenitore in ovatta sterile.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee